Danaher (DHR) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $140.30B | Exchange | NYSE |
| Sector | Healthcare | Industry | Medical - Diagnostics & Research |
| Country | US | CEO | Rainer Blair |
| IPO Date | 1978-12-29 | CAGR | 11.66% |
| Employees | 59,000 | Website | www.danaher.com |
| Div. Yield | 0.08% | Payout Ratio | 25% |
| Buy Back Yield | 0.19% | Total Yield | 0.27% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $176.85B | P/E | 25.01 | Forward P/E | 21.46 | PEG | 0.6 |
| P/S | 61.17 | P/B | 28.55 | P/CF | 235.31 | P/FCF | 286.38 |
| Sales | $25.11B | Sales 1Y | 4.56% | Sales 3Y | -10.02% | Sales 5Y | -6.03% |
| EPS | $7.98 | EPS 1Y | 19.79% | EPS 3Y | -33.69% | EPS 5Y | -25.03% |
| Sales QoQ | 5.28% | EPS QoQ | -15.17% | Sales QoQ Avg | 1.81% | EPS QoQ Avg | 17.09% |
| Gross Margin | 60.68% | Operating Margin | 20.95% | Profit Margin | 14.89% | ROCE | 6.82% |
| ROA | 4% | ROE | 7% | Altman Z Score | 3.64 | Piotroski Score | 6 |
| Current Ratio | 1.87 | Quick Ratio | 1.52 | Cash Ratio | 0.76 | Op. CF Ratio | 0.19 |
| Debt/Equity | 0.35 | Debt/Assets | 0.29 | Lt Debt/Equity | 0.48 | Lt Debt/Cap. | 0.25 |
| Intrst Cov. | 20.28 | Inventory Turnover | 3.74 | Asset Turnover | 0.3 | Receivables Turnover | 6.49 |
| Enterprise Value | $176.85B | P/E Ratio | 25.01 |
| Forward P/E | 21.46 | PEG Ratio | 0.6 |
| P/S Ratio | 61.17 | P/B Ratio | 28.55 |
| P/CF Ratio | 235.31 | P/FCF Ratio | 286.38 |
| EPS | $7.98 | EPS Growth 1Y | 19.79% |
| EPS Growth 3Y | -33.69% | EPS Growth 5Y | -25.03% |
| Revenue Growth 1Y | 4.56% | Gross Margin | 0.61% |
| Operating Margin | 0.21% | Profit Margin | 0.15% |
| ROE | 0.07% | ROA | 0.04% |
| ROCE | 0.07% | Current Ratio | 1.87 |
| Quick Ratio | 1.52 | Cash Ratio | 0.76 |
| Debt/Equity | 0.35 | Interest Coverage | 20.28 |
| Altman Z Score | 3.64 | Piotroski Score | 6 |
Danaher (DHR) valuation & financials
Danaher (DHR) has a market capitalization of $140.30B and trades at a price-to-earnings ratio of 25.0. It operates in the Healthcare sector (Medical - Diagnostics & Research).
Danaher's revenue grew +4.6% over the last year.
Danaher's next earnings report is scheduled for October 20, 2026 before market open; analysts estimate EPS of $1.96. Check the earnings calendar to see all companies reporting this week.
Danaher (DHR) — frequently asked questions
When does Danaher (DHR) report earnings next?
Danaher is expected to report earnings on October 20, 2026 before market open. Analysts estimate EPS of $1.96.
What is Danaher's market cap?
Danaher (DHR) has a market capitalization of $140.30B.
What is DHR's P/E ratio?
Danaher trades at a price-to-earnings ratio of 25.0, with trailing twelve-month EPS of $7.98.
How fast is Danaher growing?
Danaher's revenue grew +4.6% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)